{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:12:22Z","timestamp":1781727142753,"version":"3.54.5"},"reference-count":38,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This post hoc analysis in patients medically diagnosed with chronic migraine (CM) and medication\u2010overuse headache (MOH) evaluated reductions in the use of acute headache medication (AHM) and sustained changes in the diagnostic status of CM and MOH following eptinezumab treatment in the PROMISE\u20102\u00a0study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eptinezumab, a monoclonal antibody that inhibits calcitonin gene\u2010related peptide, is approved in the United States for the preventive treatment of migraine. A previous analysis showed that eptinezumab reduced monthly migraine days and was well tolerated in the subgroup of PROMISE\u20102 patients diagnosed with both CM and MOH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The phase 3, double\u2010blind, placebo\u2010controlled PROMISE\u20102\u00a0study (NCT02974153) randomized adults with CM to eptinezumab 100 mg, 300\u00a0mg, or placebo (administered intravenously every 12\u00a0weeks for up to two doses). MOH was prospectively diagnosed at screening by trained physicians based on 3\u00a0months of medication history and International Classification of Headache Disorders\u20103\u03b2 criteria. This post hoc analysis evaluated changes in total and class\u2010specific days of AHM usage, the percentage of patients using AHM at or above MOH diagnostic thresholds, and the percentage of patients experiencing monthly headache and migraine day frequency below diagnostic thresholds for MOH and\/or CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In PROMISE\u20102, 431\/1072 (40.2%) patients with CM were diagnosed with MOH (eptinezumab 100\u00a0mg,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0139; 300\u00a0mg,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0147; placebo,\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0145) and were included in this analysis. Total monthly AHM use decreased from 20.6\u00a0days\/month at baseline to 10.6\u00a0days\/month over 24\u00a0weeks of treatment (49% decrease) with eptinezumab 100\u00a0mg, from 20.7 to 10.5\u00a0days\/month (49% decrease) with eptinezumab 300\u00a0mg, and from 19.8 to 14.0\u00a0days\/month (29% decrease) with placebo. Numerically greater decreases from baseline with eptinezumab were also observed for individual drug classes. In each study month, the percentages of patients who were below MOH thresholds were numerically higher for both eptinezumab doses compared with placebo, as were the percentages of patients experiencing headache and migraine frequency below CM thresholds. Of patients with available data across the entire treatment period, 29.0% (58\/200) of patients treated with eptinezumab stopped meeting and remained below diagnostic thresholds for both CM and MOH during Weeks 1\u201324, as well as 6.3% (6\/96) of patients who received placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Across 24\u00a0weeks of treatment, eptinezumab reduced AHM use in patients diagnosed with CM and MOH. More than one\u2010fourth (29%) of patients treated with eptinezumab did not meet the diagnostic thresholds for either CM or MOH for the entire treatment period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14206","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T09:18:56Z","timestamp":1634807936000},"page":"1421-1431","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication\u2010overuse headache"],"prefix":"10.1111","volume":"61","author":[{"given":"Michael J.","family":"Marmura","sequence":"first","affiliation":[{"name":"Department of Neurology Jefferson Headache Center Thomas Jefferson University Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Biometry and Epidemiology Medical Faculty University of Duisburg\u2010Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences Stanford University Headache and Facial Pain Program Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J.","family":"Tepper","sequence":"additional","affiliation":[{"name":"Department of Neurology Geisel School of Medicine at Dartmouth Hanover New Hampshire USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle L.","family":"Diamond","sequence":"additional","affiliation":[{"name":"Diamond Headache Clinic Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal J.","family":"Starling","sequence":"additional","affiliation":[{"name":"Department of Neurology Mayo Clinic Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[{"name":"Pacific Northwest Statistical Consulting, Inc. Woodinville Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahar","family":"Mehta","sequence":"additional","affiliation":[{"name":"Lundbeck Seattle BioPharmaceuticals, Inc. Bothell Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brevig","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[{"name":"Lundbeck La Jolla Research Center San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30146-2"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03612.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008493"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413515338"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0696-8"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.j.pain.0000460346.00213.16"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0865-z"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2020.1770084"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.88.16_supplement.P2.155"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.264671"},{"key":"e_1_2_10_14_1","unstructured":"VYEPTI. Package insert.Lundbeck Seattle BioPharmaceuticals Inc.;2020."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14007"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14036"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0592-1"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1767402"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03497.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0840-8"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00586"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1636-9"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.05.003"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz052"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007497"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007452"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01173-8"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004374"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01175.x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03094.x"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-016-0612-2"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000504"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415593088"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411431309"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01631.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2006.01198.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14206","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:20:05Z","timestamp":1762089605000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/head.14206"],"URL":"https:\/\/doi.org\/10.1111\/head.14206","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"assertion":[{"value":"2021-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}